JAK/STAT signaling
JAK/STAT signaling inhibitors are compounds that disrupt the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway, which is involved in cytokine signaling, cell growth, and immune response. These inhibitors are important tools in studying the regulation of this pathway and its role in various diseases, including cancers, immune disorders, and inflammatory conditions. JAK/STAT inhibitors are also being developed as targeted therapies for these diseases. At CymitQuimica, we provide a wide selection of high-quality JAK/STAT signaling inhibitors to support your research in molecular biology, oncology, and immunology.
Subcategories of "JAK/STAT signaling"
Found 362 products of "JAK/STAT signaling"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Brepocitinib
CAS:Brepocitinib (PF-06700841) is a potent dual JAK1/TYK2 inhibitor (IC50s: 17 nM/23 nM). Brepocitinib also inhibits JAK2/3 (IC50s: 77 nM/6.49 μM).Formula:C18H21F2N7OPurity:99.82%Color and Shape:SolidMolecular weight:389.4Ref: TM-TQ0010
1mg34.00€2mg46.00€5mg66.00€10mg99.00€25mg205.00€50mg371.00€100mg595.00€200mg833.00€1mL*10mM (DMSO)73.00€JAK-IN-4
CAS:JAK-IN-4 is a prodrug of a JAK inhibitor, effective in murine collagen induced arthritis model.Formula:C18H21N4Na2O6PPurity:98%Color and Shape:SolidMolecular weight:466.341NMS-P953
CAS:NMS-P953: JAK2 inhibitor, reduces tumor growth in SET-2 model, confirmed in vivo action, good pharmacokinetics and safety.Formula:C16H11ClF3N5OColor and Shape:SolidMolecular weight:381.74PIM1-IN-4
CAS:PIM1-IN-4: strong PIM1 inhibitor, also blocks SGK-1, PKA, CaMK-1, GSK3β, MSK1; promising for cancer studies.Formula:C27H25BrCl2CuN6OPurity:98%Color and Shape:SolidMolecular weight:663.88JAK-IN-25
CAS:JAK-IN-25 (compound 19), a potent JAK inhibitor, exhibits IC50 values of 6 nM for TYK2, 21 nM for JAK1, 8 nM for JAK2, and 1051 nM for JAK3.Formula:C19H17N5O4Purity:98%Color and Shape:SolidMolecular weight:379.37STAT3-IN-B9
CAS:STAT3-IN-B9 (B9) is an inhibitor of abnormal STAT3 activation and inhibits the proliferation of tumor cells including MDA-MB-468, MDA-MB-231, and DU145.Formula:C20H13NO5SPurity:98.19%Color and Shape:SolidMolecular weight:379.39Ref: TM-T28865
1mg109.00€2mg154.00€5mg235.00€10mg349.00€25mg532.00€50mg745.00€100mg999.00€200mg1,333.00€1mL*10mM (DMSO)255.00€Nezulcitinib
CAS:Nezulcitinib (TD-0903) is an inhaled pan-JAK inhibitor targeting COVID-19-related acute lung injury.Formula:C30H37N7O2Color and Shape:SolidMolecular weight:527.66STAT6-IN-3
CAS:STAT6-IN-3 (Compound 18a) serves as an inhibitor of STAT6 with an IC50 value of 44 nM, specifically targeting the Src Homology 2 (SH2) domain.Formula:C32H35IN3O7PPurity:98%Color and Shape:SolidMolecular weight:731.51FM-479
CAS:FM-479, a structural analog of FM-381, lacks inhibition of JAK3/kinases within 100-300 nM, serving as FM-381's negative control.
Formula:C25H26N6O2Purity:98%Color and Shape:SolidMolecular weight:442.523HS94
CAS:HS94 (DAPK3 inhibitor HS94) is a selective and potent DAPK3 inhibitor with a Ki value of 126 nM for Pim kinase inhibition and can be used to study hypertension.
Formula:C15H15N5O2SPurity:95.04%Color and Shape:SolidMolecular weight:329.38STAT6-IN-2
CAS:STAT6-IN-2(R)-84 is a STAT6 inhibitor that inhibits the secretion of eotaxin-3 and the tyrosine phosphorylation of STAT6.Formula:C28H31N5O2Purity:99.67%Color and Shape:SolidMolecular weight:469.58JAK-IN-3
CAS:JAK-IN-3 is a potent JAK inhibitor that inhibits JAK3, JAK1, TYK2, and JAK2, and can be used for the study of immune system disorders.Formula:C18H20N4O3Purity:98.04% - 98.19%Color and Shape:SolidMolecular weight:340.38Ref: TM-T11704
1mg126.00€2mg178.00€5mg304.00€10mg492.00€25mg982.00€50mg1,558.00€100mg2,538.00€200mg3,402.00€1mL*10mM (DMSO)334.00€Tyk2-IN-15
CAS:Tyk2-IN-15 (Compound 97) is a selective inhibitor of tyrosine kinase 2 (Tyk2) with an IC50 value ≤ 10 nM for Tyk2-JH2. It is utilized in the research of inflammatory and autoimmune diseases [1].
Formula:C21H25F2N7OColor and Shape:SolidMolecular weight:429.47Tyk2-IN-17
CAS:Tyk2-IN-17 (compound 185) effectively inhibits TYK2 [1].Formula:C20H20F2N8OColor and Shape:SolidMolecular weight:426.42JAK1/TYK2-IN-4
CAS:JAK1/TYK2-IN-4 serves as a dual inhibitor targeting both JAK and TYK2, displaying IC50 values of 39 nM and 21 nM, respectively. It is also orally bioavailable [1].Formula:C17H23N7OColor and Shape:SolidMolecular weight:341.41JAK3-IN-11
CAS:JAK3-IN-11: potent oral JAK3 inhibitor (IC50=1.7 nM), noncytotoxic, >588-fold selectivity, blocks T-cell growth; useful in autoimmune research.Formula:C23H23N5O2Color and Shape:SolidMolecular weight:401.46JAK1-IN-9
CAS:JAK1-IN-9 (compound 23a) is a potent, selective inhibitor of JAK1, demonstrating an IC50 of 72 nM.Formula:C16H13IN6Color and Shape:SolidMolecular weight:416.22STAT3-IN-8
CAS:"STAT3-IN-8 (compound H172) is a potent inhibitor of STAT3 with potential applications in cancer research [1]."Formula:C19H7F7N2O3Purity:98%Color and Shape:SolidMolecular weight:444.26WZ-2-033
CAS:WZ-2-033 is a potent STAT3 inhibitor. It inhibits proliferation, colony survival, migration, and invasion of MDA-MB-231, HCC70, and MDA-MB231-4175 cells, with IC50 values of 0.7, 1.3, and 1.3 μM respectively.Formula:C25H18F3N3O4SColor and Shape:SolidMolecular weight:513.49JAK2 JH2 binder-1
CAS:JAK2 JH2 binder-1: potent, selective, Ki=37.1 nM, potential for studying myeloproliferative neoplasms.Formula:C29H25N7O6SColor and Shape:SolidMolecular weight:599.62Ten01
Ten01 exhibits a 5.0 nM inhibition of JAK1 kinase.Formula:C18H20F6N4OColor and Shape:SolidMolecular weight:422.37STAT3-IN-7
CAS:STAT3-IN-7, an orally active aryl sulfonamido azetidine compound, serves as a STAT3 inhibitor with anticancer activities.Formula:C30H26F5N5O4SColor and Shape:SolidMolecular weight:647.62JAK1/TYK2-IN-3
JAK1/TYK2-IN-3, orally active, selectively inhibits TYK2 (IC50: 6 nM), JAK1 (37 nM), JAK2 (140 nM), JAK3 (362 nM), and has anti-inflammatory effects.Color and Shape:SolidJAK-IN-23
"JAK-IN-23: oral dual JAK/STAT & NF-κB inhibitor; JAK1 (IC50: 8.9 nM), JAK2 (15 nM), JAK3 (46.2 nM); for IBD research."Formula:C23H22Cl2N4OColor and Shape:SolidMolecular weight:441.35TYK2 ligand 2
CAS:TYK2ligand 2 is the TYK2 ligand of PROTACTYD-68. TYD-68 is a highly potent and selective CRBN-recruiting TYK2 PROTAC degrader with a DC50 value of 0.42 nM.Formula:C24H20FN7O4Color and Shape:SolidMolecular weight:489.458iBFAR2
CAS:iBFAR2, an inhibitor of BFAR, restores the CD8+ tumor-resident memory T cell subset against solid tumors. It promotes the binding of JAK2-STAT1 and enhances the phosphorylation of STAT1.
Formula:C19H15F3N2O2Color and Shape:SolidMolecular weight:360.33JAK3 covalent inhibitor-1
CAS:JAK3 Covalent Inhibitor-1 is a compound characterized by its potent and selective inhibition of Janus kinase 3 (JAK3), possessing an IC50 of 11 nM andFormula:C22H17FN6O2SPurity:98%Color and Shape:SolidMolecular weight:448.47CP-352664
CAS:CP-352664 is a JAK inhibitor with potency against JAK3, exhibiting an EC50 value of 210 nM. It holds potential for use in research related to organ transplant rejection and autoimmune diseases, such as rheumatoid arthritis.Formula:C18H18N4Color and Shape:SolidMolecular weight:290.36Tyk2-IN-3
CAS:Tyk2-IN-3 is an inhibitor of Tyk2 pseudokinase (IC50: 485 nM).Formula:C25H24N6O3S2Purity:98%Color and Shape:SolidMolecular weight:520.63(3S,4R)-Tofacitinib
CAS:(3S,4R)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib is a JAK3 inhibitor(IC50 : 1 nM).Formula:C16H20N6OPurity:98%Color and Shape:SolidMolecular weight:312.37JAK2-IN-11
CAS:JAK2-IN-11 (Example 6) is a JAK2 kinase inhibitor with potent antitumor activity, exhibiting an IC50 of ≤10 nM against JH2 BIND WT/V617F. This compound effectively suppresses tumor growth.Formula:C31H31F3N8O4Color and Shape:SolidMolecular weight:639.64SI-109
CAS:SI-109 is a potent inhibitor of STAT3 SH2 domain (Ki=9 nM),and with antitumor activity.Formula:C40H44F2N7O9PPurity:98%Color and Shape:SolidMolecular weight:835.79PF-06263276
CAS:PF-06263276 selectively inhibits pan-JAK with IC50: JAK1 (2.2 nM), JAK2 (23.1 nM), JAK3 (59.9 nM), TYK2 (29.7 nM).Formula:C31H31FN8O2Purity:98%Color and Shape:SolidMolecular weight:566.63JAK3-IN-7
CAS:JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) for the treatment of rejection in organ transplantation, graft-versus-host reaction afterFormula:C17H20N6OPurity:98.81%Color and Shape:SolidMolecular weight:324.38lirucitinib
CAS:Lirucitinib is a JAK inhibitor known for its anti-inflammatory properties.Formula:C16H25N5OSColor and Shape:SolidMolecular weight:335.468AZ-3
CAS:AZ-3 is a potent and selective JAK1 inhibitor (IC50: 34 nM).Formula:C20H28FN7Purity:98%Color and Shape:SolidMolecular weight:385.48LNK01004
CAS:LNK01004 is a JAK inhibitor that exhibits potent inhibitory effects on JAK1 (IC50: 10 nM), JAK2 (IC50: ＜0.51 nM), and TYK2 (IC50: 1.0 nM). It can concurrently inhibit multiple cytokine-induced p-STAT signaling pathways and is applicable for research on diseases such as atopic dermatitis.Formula:C26H31N7O2Color and Shape:SolidMolecular weight:473.57Milpecitinib
CAS:Milpecitinib (Compound 21a) is a potent and selective Janus tyrosine kinase (JAK) inhibitor with anti-inflammatory properties. It shows promise for research in cancer and inflammatory diseases.Formula:C20H20N4O2SColor and Shape:SolidMolecular weight:380.463Prohibitin ligand 1
Compound 22i, a prohibitin ligand, protects the heart at nanomolar levels by inducing STAT3 phosphorylation.Formula:C20H22N2OColor and Shape:SolidMolecular weight:306.4GDC-0339
CAS:GDC-0339: oral Pim kinase inhibitor for multiple myeloma (Kis: Pim1 - 0.03 nM, Pim2 - 0.1 nM, Pim3 - 0.02 nM), well-tolerated.Formula:C20H22F3N7OSColor and Shape:SolidMolecular weight:465.5CEE321
CAS:CEE321 is an effective pan-JAK inhibitor with an IC50 of 54 nM. It effectively inhibits biomarkers associated with atopic dermatitis.Formula:C18H16ClN5OColor and Shape:SolidMolecular weight:353.806JAK-IN-19
JAK-IN-19 inhibits JAK (pIC50: 7.2, 7.7), less so for VEGFR2 (7.0) and Aurora B (5.8).Formula:C26H36FN5O2Color and Shape:SolidMolecular weight:469.59Cenacitinib
CAS:Cenacitinib is an effective inhibitor of Janus kinase (Janus kinase) and possesses anti-inflammatory activity.Formula:C19H19F2N7O3Color and Shape:SolidMolecular weight:431.40GDC-9918
CAS:GDC-9918 (compound GDC-9918) is an inhibitor of Janus kinases.Formula:C20H18F2N6O5SColor and Shape:SolidMolecular weight:492.46STAT3-IN-35
CAS:STAT3-IN-35 is a STAT3 inhibitor that binds to the SH2 domain. This compound inhibits the phosphorylation of STAT3 and exhibits antiproliferative activity in triple-negative breast cancer (TNBC) cell lines. Additionally, STAT3-IN-35 has demonstrated toxicity and potent antitumor activity in TNBC xenograft models.Formula:C21H23NO4Color and Shape:SolidMolecular weight:353.41Tyk2-IN-20
CAS:Tyk2-IN-20 (Example 289) is an effective inhibitor of Tyk2 with an IC50 value below 5 nM. Additionally, it inhibits JAK1, JAK2, and JAK3 with IC50 values under 100 nM. This compound is utilized for the research of inflammatory diseases.Formula:C24H25N7O2Color and Shape:SolidMolecular weight:443.50STAT3-IN-36
CAS:STAT3-IN-36 (compound 11g) is a tritarget inhibitor that selectively targets LRPPRC, STAT3, and CDK1, exhibiting potent anticancer activity. This compound binds to LRPPRC, STAT3, and CDK1, demonstrating more effective anticancer effects than those of TMF or Capecitabine. Additionally, STAT3-IN-36 exhibits an IC50 value of 1.8 μM in HGC27 cells.Formula:C30H24F2N2O9S2Color and Shape:SolidMolecular weight:658.65Tyk2-IN-10
CAS:Tyk2-IN-10 acts as an inhibitor of the Tyrosine Kinase 2 (Tyk2)-mediated signaling pathway, which plays a role in inflammation regulation.Formula:C25H27N5O3Color and Shape:SolidMolecular weight:445.51Londamocitinib
CAS:Londamocitinib (JAK1-IN-7) is a selective and potent JAK1 inhibitor with anti-inflammatory activity.Formula:C28H31F2N7O4SPurity:98.64% - 99.56%Color and Shape:SolidMolecular weight:599.65Ref: TM-T11706
1mg170.00€5mg416.00€10mg567.00€25mg858.00€50mg1,108.00€100mg1,485.00€1mL*10mM (DMSO)537.00€Tyk2-IN-14
CAS:Tyk2-IN-14, a small molecule inhibitor of TYK2, is significant in treating inflammatory diseases and conditions linked to hypersecretion of IFNa and interferons [1].Formula:C22H21N9O2Color and Shape:SolidMolecular weight:443.46Pim-1 kinase inhibitor 6
CAS:Pim-1 kinase inhibitor 6 (Compound 4d) is a robust inhibitor of Pim-1 kinase, demonstrating an IC 50 of 0.46 μM. It significantly exhibits cytotoxic effects on cancer cells [1].Formula:C21H10BrCl2N3Color and Shape:SolidMolecular weight:455.1315(R)-Lipoxin A4
CAS:Lipid-derived lipoxins are produced at the site of vascular and mucosal inflammation where they down-regulate polymorphonuclear leukocyte recruitment andFormula:C20H32O5Color and Shape:SolidMolecular weight:352.47YLIU-4-105-1
CAS:YLIU-4-105-1 is a type II JAK2 inhibitor. Demonstrating in vivo pharmacological activity, YLIU-4-105-1 reduces splenic weight, decreases blood reticulocyte counts in a dose-dependent manner, and inhibits pSTAT5.Formula:C32H34F3N7O2Color and Shape:SolidMolecular weight:605.65JDTic
CAS:JDTic, a 4-phenylpiperidine derivative distantly related to analgesics like meperidine and ketobemidone and more closely to the mu opioid antagonist alvimopan, exhibits a notably long duration of action, maintaining effects in animals for weeks following a single dose. This duration is not due to irreversible binding to the kappa opioid receptor but rather to altered activity of c-Jun N-terminal kinases. As a highly selective antagonist for the κ-opioid receptor, without influencing the μ- or δ-opioid receptors, JDTic has shown potential in animal studies for producing antidepressant and anxiolytic effects. It also demonstrates promise in treating addiction to substances such as cocaine and morphine, distinguishing itself structurally from other kappa antagonists like norbinaltorphimine.Formula:C28H39N3O3Color and Shape:SolidMolecular weight:465.63(3R,4S)-Tofacitinib
CAS:(3R,4S)-Tofacitinib, the less active enantiomer of Tofacitinib, is a JAK3 inhibitor with an IC50 of 1 nM.Formula:C16H20N6OPurity:98%Color and Shape:SolidMolecular weight:312.37JAK2-IN-9
CAS:Compound A8, known as JAK2-IN-9, is a selective JAK2 inhibitor with an IC50 of 5 nM.
Formula:C20H24N6O2SPurity:98%Color and Shape:SolidMolecular weight:412.51DPP
CAS:DPP, a Platinum(IV) complex with a pterostilbene-derived axial ligand, inhibits the JAK2-STAT3 pathway in breast cancer (BC) cells, demonstrating
Formula:C36H40Cl2N2O10PtPurity:98%Color and Shape:SolidMolecular weight:926.7JAK-IN-34
CAS:JAK-IN-34 (compound 11n) is a potent inhibitor of Janus kinases (JAKs), demonstrating IC50 values of 0.40 nM for JAK1, 0.83 nM for JAK2, 2.10 nM for JAK3,
Formula:C27H26N6OPurity:98%Color and Shape:SolidMolecular weight:450.53STAT3-IN-18
CAS:STAT3-IN-18 (compound SPP), a platinum (IV) complex featuring an axial ligand from sandalwood, suppresses the JAK2-STAT3 pathway in breast cancer (BC) cells and
Formula:C18H24Cl2N2O6PtPurity:98%Color and Shape:SolidMolecular weight:630.38JAK-IN-27
CAS:JAK-IN-27, also known as compound 1, is an orally active, potent inhibitor of the JAKS family kinases, displaying inhibitory concentrations (IC50s) of 3.0 nM
Formula:C20H21F2N7OPurity:98%Color and Shape:SolidMolecular weight:413.42JAK1-IN-11
CAS:JAK1-IN-11 (compound 11) serves as a potent inhibitor of Janus kinases, exhibiting nanomolar inhibitory concentrations with IC50 values of 0.02 nM (JAK1) and 0.
Formula:C26H36N6O4SPurity:98%Color and Shape:SolidMolecular weight:528.67JAK1-IN-10
CAS:JAK1-IN-10 (compound 9), a cyano-substituted cyclic hydrazine derivative, functions as a potent and selective inhibitor of JAK1 [1].
Formula:C15H17N7Purity:98%Color and Shape:SolidMolecular weight:295.34
